Turkey’s Zer Recognized as “Product Challenger” in Global Procurement Ecosystem
4.4.2022 12:00:00 EEST | Business Wire | Press release
Zer , a Turkey-based company specializing in strategic procurement and sourcing management, has been included – for the first time – on the prestigious Provider Lens™ Quadrant Report of Information Services Group (ISG), a leading global technology research and advisory firm. Updated on a quarterly basis, ISG Provider Lens™ is a practitioner-led service provider comparison, empowered by ISG’s advisory experience and data-driven research.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220401005382/en/
For the first time, Turkish procurement services firm Zer has been listed on ISG’s Provider Lens™ Quadrant Report (Photo: Business Wire)
A subsidiary of Turkey's Koç Group, Zer took its place in ISG Provider Lens™ report in both the “Procurement BPO Services” and the “Digital Transformation Services” quadrants for both large accounts and midmarket categories. Zer featured in the same quadrant with the firms who consult to industry giants on Fortune 50.
Zer's brand Promena, which is a strategic procurement software, meanwhile, also made the list (in the “Software Platforms and Solutions” quadrant for large accounts), taking a place alongside globally-recognized service providers.
‘Closely followed by procurement professionals’
According to Zer General Manager Mehmet Apak, ISG’s Provider Lens List is extremely influential in the competitive world of digital solutions. “It is closely followed by supply chain and procurement professionals from all over the world,” Apak says. “Lists like ISG Provider Lens™ serve to raise brand awareness in international markets and enhance Turkey's role in the global procurement ecosystem.”
Underlining that global demand for Promena had recently increased by 50%, Apak went on to assert that “Zer’s inclusion in the ISG Provider Lens™ “is a natural reflection of the qualities we bring to all stakeholders – qualities such as resilience and agility.” Both these qualities are crucial, he adds, “in a business environment that is increasingly unpredictable and in which priorities are constantly changing.”
A ‘Value Leader’ in the global procurement sector
Zer‘s strategic procurement software Promena has also been recognized by SpendMatters, Capgemini, Capterra, Procurement Leaders, Art of Procurement and Sourceforge, all of which follow top digital solutions and procurement brands. Since 2019, Promena was included in SpendMatters’ influential Solutionmap Report. Last year, the same report described the company as a “Value Leader” in the global procurement sector.
“We’re pleased that our company is drawing international attention,” Apak says. “In the digital age, procurement and supply chain management is more essential than ever. It lets businesses connect with the rest of the world, keep costs and risks in check, and overcome the hurdles associated with digital transformation.”
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220401005382/en/
Contact information
Tülay Genç
support@b2press.com
+90 (212) 635 70 68
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
